272 results
8-K
EX-99.1
MDGL
Madrigal Pharmaceuticals, Inc.
7 Aug 24
Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates
7:06am
the community on the clinical benefits of Rezdiffra, supporting the creation of care pathways for patients at physician offices, driving breadth … that interventions that can delay or prevent progression may reduce morbidity and mortality and deliver cost benefits.
Second-Quarter 2024 Financial
8-K
EX-10.1
MDGL
Madrigal Pharmaceuticals, Inc.
27 Jun 24
Departure of Directors or Certain Officers
4:28pm
, in the Administrator’s sole discretion, to designate those payments or benefits that should be reduced or eliminated so as to avoid having such payments or benefits … to a Participant (and any benefits derived therefrom).
37. GOVERNING LAW.
This Plan shall be construed and enforced in accordance with the law
8-K
EX-1.1
MDGL
Madrigal Pharmaceuticals, Inc.
7 May 24
Entry into a Material Definitive Agreement
4:36pm
as shall be appropriate to reflect the relative benefits received by the Company, on the one hand, and TD Cowen, on the other. The relative
- 20 -
benefits … of contribution shall be made in such proportion as is appropriate to reflect not only the relative benefits referred to in the foregoing sentence but also
424B3
MDGL
Madrigal Pharmaceuticals, Inc.
7 May 24
Prospectus supplement
4:34pm
and projections regarding potential NASH or NAFLD and potential patient benefits with resmetirom, including future NASH resolution, safety, fibrosis … , and potential NASH or NAFLD patient risk profile benefits with resmetirom;
The predictive power of liver fat, liver volume changes or MAST scores
424B5
zwsfjwwjlml
7 May 24
Prospectus supplement for primary offering
4:29pm
S-3ASR
pj4vzwtveoqg x5
7 May 24
Automatic shelf registration
4:06pm
S-3ASR
EX-4.6
eeblzuey
7 May 24
Automatic shelf registration
4:06pm
8-K
EX-99.1
yqrxe4guvypu
7 May 24
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
7:06am
8-K
EX-1.1
i5f74cwe98 bza
20 Mar 24
Entry into a Material Definitive Agreement
4:11pm
424B5
szn 9foeoy239p4pny
20 Mar 24
Prospectus supplement for primary offering
4:06pm
424B5
2j4t0dm0e8kgqt3k
18 Mar 24
Prospectus supplement for primary offering
4:08pm
8-K
EX-99.1
zr8oh3n8i2nn7
14 Mar 24
Regulation FD Disclosure
6:47pm
8-K
EX-99.2
l2l0z6dqq6uc5
14 Mar 24
Regulation FD Disclosure
6:47pm
8-K
5brv1
28 Feb 24
Departure of Directors or Certain Officers
7:10am
8-K
EX-99.1
lpf7i
28 Feb 24
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full
7:01am